Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. mx.investing.com › news › company-newsHOOKIPA anuncia el desdoblamiento inverso de sus acciones para...

    Hace 1 día · HOOKIPA Pharma es una empresa en fase clínica que desarrolla inmunoterapias novedosas utilizando su plataforma de arenavirus patentada, dirigida a enfermedades graves mediante la amplificación de las respuestas de células T específicas. Su cartera de productos incluye, entre otras, terapias para cánceres positivos al virus del papiloma ...

  2. ir.hookipapharma.com › news-releases › news-release-detailsHOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock...

    Hace 19 horas · July 8, 2024 at 7:01 AM EDT. NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of common stock will be ...

  3. ir.hookipapharma.com › news-releases › news-release-detailsHOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical...

    1 de jul. de 2024 · HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

  4. finance.yahoo.com › news › hookipa-pharma-announces-effective-date-110100613HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock...

    Hace 1 día · NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...

  5. www.marketscreener.com › quote › stockHOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical...

    Hace 6 días · NEW YORK - HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV.

  6. www.marketbeat.com › instant-alerts › nasdaq-hook-stock-split-2024/07/08Hookipa Pharma (NASDAQ:HOOK) Shares Scheduled to Reverse ... -...

    Hace 1 día · Hookipa Pharma Price Performance. HOOK traded down $0.05 during midday trading on Monday, reaching $0.51. 1,566,233 shares of the company's stock traded hands, compared to its average volume of 717,963. The stock has a market capitalization of $50.69 million, a price-to-earnings ratio of -1.02 and a beta of 0.81.

  7. www.clinicaltrialsarena.com › news › hookipa-pharma-hiv-trialHOOKIPA Pharma doses first subject in trial of HIV vaccine

    2 de jul. de 2024 · US-based biotechnology company HOOKIPA Pharma has dosed the first subject in a Phase Ib clinical trial of HB-500, a therapeutic vaccine candidate for human immunodeficiency virus (HIV).

  1. Búsquedas relacionadas con hookipa tienda

    hookipa tienda santiago